Mangalam Drugs (MANGALAM) | Stock Overview & Key Data
Mangalam Drugs Performance Comparison
Stock Range
Today's Range
Low: ₹79.50
High: ₹84.21
on August 22, 2025
52 Week Range
Low: ₹70.10
High: ₹144.99
on May 9, 2025
on August 26, 2024
All-Time High: ₹442.40 on December 7, 2015
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR1.3B
EPS
-6.17
P/E Ratio (TTM)
19.47
Forward P/E
N/A
P/B Ratio
0.81
PEG Ratio
-0.03
Div. Yield
N/A
ROE
4.51%
Beta
0.036
Debt to Equity
64.59
Financial Highlights
Profitability
Gross Margin
20.07%
Operating Margin
-15.65%
Profit Margin
-3.27%
Returns and Earnings
Return on Assets (TTM)
1.83%
Return on Equity (TTM)
4.51%
EBITDA
INR363.3M
Net Income (TTM)
INR-97.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR188.45
Quarterly Revenue Growth (YoY)
-25.20%
Quarterly Earnings Growth (YoY)
-25.21%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Mangalam Drugs MANGALAM | 1.30B Small-cap | -3.64% | -12.18% | 1.45% | -22.16% | -33.38% | -39.97% | -46.01% | -48.41% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 0.07% | -2.94% | -5.16% | -0.08% | -13.09% | -7.63% | 86.35% | 195.13% |
| Divi's Laboratories DIVISLAB | 1.64T Large-cap | -1.70% | -9.87% | -8.00% | 4.71% | -0.74% | 24.14% | 68.03% | 84.18% |
| Sun Pharma Advanced SPARC | 47.77B Small-cap | 3.43% | -9.83% | -12.50% | 12.07% | -27.72% | -34.90% | -37.57% | -23.72% |
| Aarti Drugs AARTIDRUGS | 44.80B Small-cap | -3.22% | -13.59% | -0.59% | 21.36% | 3.40% | -16.47% | 7.52% | -35.72% |
| Sequent Scientific SEQUENT | 44.30B Small-cap | -0.44% | -6.77% | -2.09% | 9.71% | -5.23% | 5.57% | 52.75% | 30.80% |
Ownership & Short Interest
Insider Ownership
55.63%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
47K
Average 90-Day Volume
57K
Mangalam Drugs Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Mangalam Drugs would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is MANGALAM's 52-week high and low?
- In the last 52 weeks, Mangalam Drugs reached a high of ₹144.99 (on August 26, 2024) and a low of ₹70.10 (on May 9, 2025).
- What is the market cap and P/E ratio for MANGALAM?
- Curious about Mangalam Drugs's size and valuation? Its market capitalization stands at 1.30B. When it comes to valuation, the P/E ratio (trailing twelve months) is 19.47, and the forward P/E (looking ahead) is N/A.
- Does MANGALAM pay dividends? If so, what's the yield?
- As for dividends, Mangalam Drugs isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Mangalam Drugs's main competitors or similar companies to consider before investing?
When looking at Mangalam Drugs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -7.63% 86.35% Divi's Laboratories
DIVISLAB1.64T Healthcare Drug Manufacturers - Specialty & Generic 24.14% 68.03% Sun Pharma Advanced
SPARC47.77B Healthcare Drug Manufacturers - Specialty & Generic -34.90% -37.57% Aarti Drugs
AARTIDRUGS44.80B Healthcare Drug Manufacturers - Specialty & Generic -16.47% 7.52% Sequent Scientific
SEQUENT44.30B Healthcare Drug Manufacturers - Specialty & Generic 5.57% 52.75% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Mangalam Drugs and Organics Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Mangalam Drugs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 4.51%, the Debt to Equity ratio from the most recent quarter is 64.59, and its Gross Profit Margin stands at 20.07%.
- What is the recent revenue and earnings growth for MANGALAM?
- Looking at Mangalam Drugs's growth, its revenue over the trailing twelve months (TTM) was INR3B. Compared to the same quarter last year (YoY), quarterly revenue grew by -25.20%, and quarterly earnings saw a YoY growth of -25.21%.
- How much of MANGALAM stock is held by insiders and institutions?
- Wondering who owns Mangalam Drugs stock? Company insiders (like executives and directors) hold about 55.63% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.